Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
AIDS Res Hum Retroviruses
; 15(15): 1333-8, 1999 Oct 10.
Article
em En
| MEDLINE
| ID: mdl-10515148
ABSTRACT
Hydroxyurea and didanosine treatment suppressed HIV replication for more than 2 years, in the absence of viral breakthrough, in chronically infected patients. The profile of viral load reduction was unusual for a two-drug combination, since a continuous gradual decrease in viremia persisted despite residual viral replication. The increase in CD4+ T cell counts was not robust. However, unlike those of patients treated by other therapies, CD4+ T lymphocytes were functionally competent against HIV, mediating a vigorous HIV-specific helper T cell response in half of these patients. In addition, the percentages of naive CD4+ and CD8+ T lymphocytes were not different from those in uninfected individuals. These results demonstrate that prolonged antiretroviral therapy with a simple, well-tolerated combination of two affordable drugs can lead to sustained control of HIV, normalization of immune parameters, and specific anti-HIV immune response.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Didanosina
/
Inibidores da Síntese de Ácido Nucleico
/
Fármacos Anti-HIV
/
Hidroxiureia
Limite:
Humans
Idioma:
En
Revista:
AIDS Res Hum Retroviruses
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Itália